ELISA kits for detecting anti-SARS-CoV-2 antibodies (COVID-19)

Quantitative detection of antibodies (IgG, IgM and IgG + IgM)

Galileo, the first Brazilian company to obtain ANVISA’s CBPF for local development and production of the entire manufacturing flow for high-performance clinical diagnostic kits, presents its ELISA kits.

Antibody tests available
  • Detection of anti-SARS-CoV-2 IgM (ELISA)
  • Detection of anti-SARS-CoV-2 IgG (ELISA)
  • Detection of anti-SARS-CoV-2 IgM and IgG (ELISA)
Intended use

The enzyme immunoassay by ELISA allows for the quantitative determination of the presence and levels of human antibodies of IgM and IgG classes against SARS-Cov-2. The kits are complete for in-vitro diagnosis and clinical analyses, including all inputs for quality control.

It is recommended for:

  • Identification of individuals previously infected with SARS-CoV-2.
  • Seroprevalence and epidemiological studies.
  • Facilitate contact tracing.
  • Identification of potential convalescent plasma donors.
  • Evaluation of immunological responses to vaccines.
  • Potential aid for the diagnosis of COVID-19 in patients that are negative for RT-PCR, and who manifest later during the course of the disease.
Typical antibody response to viral infection

IgM Antibodies

The test detects IgM antibodies, wich are typically the first antibodies produced by the immune system against attacks by the virus.

An IgM-positive test indicates recent exposure to the virus and initiation of an immune response.

IgM positivity indicates that the patient may still be infected, or has recently recovered from viral infection.

IgG Antibodies

The test detects IgG antibodies, which usually emerge 7 to 10 days after the appearance of COVID-19 simptoms.

IgG antibodies remain in the blood after the infection has passed, indicating virus infection and immune memory.

To date, the degree of protection offered by antibodies against re-infection is unknown, as is the length of time that IgG antibodies remain detectable after exposure to the virus.

Response Time

2 hours (from sample collection to result)


Human serum or plasma in the presence or absence of EDTA, heparin or citrate. The results of Galileo Biotech kits are not affected by endogenous interferences found in serum (ie, hemoglobin, bilirubin, cholesterol, etc.).


6 months refrigerated or 3 months after opening.


All kits are approved and registered by ANVISA.